Het volume van chirurgische ingrepen en de impact ervan op ... - KCE
Het volume van chirurgische ingrepen en de impact ervan op ... - KCE
Het volume van chirurgische ingrepen en de impact ervan op ... - KCE
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
164 Volume Outcome <strong>KCE</strong> reports 113<br />
6.3.7 Discussion<br />
PCI is one of those procedures for which <strong>volume</strong> thresholds have be<strong>en</strong> established. The<br />
US Ag<strong>en</strong>cy for Healthcare Research and Quality (AHRQ) applies a lower threshold of<br />
>200 PTCA per year and an upper threshold of >400 PTCA per year. 29 The US<br />
Leapfrog Group uses the cut off of 400 PCI per year to select provi<strong>de</strong>rs. 126 Finally, the<br />
American College of Cardiology/American Heart Association recomm<strong>en</strong>ds more than<br />
400 PCI per year per hospital and at least 75 PCI per year for <strong>op</strong>erators. Hospitals that<br />
perform less than 200 PCI per year are labelled as low-<strong>volume</strong> hospitals. 279<br />
6.3.7.1 External validation of the <strong>de</strong>finition of the procedure<br />
The external validation is based on data from the Belgian Working Group for<br />
Interv<strong>en</strong>tional Cardiology (BWGIC) and the Belgian Association for Cardio-Thoracic<br />
Surgery (BACTS) for the year 2004 in Belgium, as published in <strong>KCE</strong> report 66 (table 1.2<br />
on page 11 in this report). 265<br />
Table 6.36: PCI: Types of st<strong>en</strong>ts<br />
<strong>KCE</strong> project 2004<br />
Volume Outcome<br />
BWGIC 2004 265<br />
Number Pct. Number Pct.<br />
Plain balloon angi<strong>op</strong>lasty 2 144 10% 2 108 9%<br />
Bare Metal St<strong>en</strong>t (BMS) 15 431 68% 15 696 67%<br />
Drug Eluting St<strong>en</strong>t (DES) 2 776 12% 5 622 24%<br />
No information 2 210 10% - -<br />
Total PCI 22 561 100% 23 426 100%<br />
The total number of PCI is very comparable, but the number of DES is a lot less in our<br />
database (i.e. 50%) than registered in the BWGIC register. This could be explained by<br />
the reimbursem<strong>en</strong>t criteria for DES in Belgium. In 2004, there was only one approved<br />
indication for reimbursem<strong>en</strong>t i.e. diabetes. Neyt et al. m<strong>en</strong>tioned that DES were also<br />
used in non-diabetics (about 14% of non-diabetics received DES or a combination of<br />
DES and BMS during their PCI in 2004). In these cases, the hospitals have to bear the<br />
additional cost themselves and can not invoice the NIHDI co<strong>de</strong> 686464. Experts that<br />
were consulted for <strong>KCE</strong> report 66, suggested that DES were also implanted in nondiabetics<br />
with a high risk of re-st<strong>en</strong>osis, such as chronic total occlusion, in-st<strong>en</strong>t rest<strong>en</strong>osis<br />
after prior BMS, multi-vessel st<strong>en</strong>ting, etc. On the other hand, however, Neyt<br />
et al. showed that other factors played a role as well. Pati<strong>en</strong>ts in a private room, for<br />
example, had a higher probability of getting a DES. 265<br />
6.3.7.2 Summarized results of literature review<br />
The systematic literature search id<strong>en</strong>tified six systematic reviews in which the VOA for<br />
PCI was studied. 1, 5, 59, 60, 64, 67 These systematic reviews discussed 41 primary studies of<br />
which 23 were published betwe<strong>en</strong> 2000 and 2005. 282-304<br />
The discussion below will primarily be based on the evid<strong>en</strong>ce report by the German<br />
Institute for Quality and Effici<strong>en</strong>cy in Health Care (IQWiG) because it dates from 2006<br />
and was assessed as very good quality (see App<strong>en</strong>dix 7). 67 Additionally, several primary<br />
studies will be used for the discussion, especially those published in 2004 and 2005<br />
because they allow an evaluation of the <strong>volume</strong>-outcome relationship in contemporary<br />
PCI practice where coronary st<strong>en</strong>ts and new anti-platelet ag<strong>en</strong>ts (i.e. glyc<strong>op</strong>rotein IIb/IIIa<br />
receptor blockers) are wi<strong>de</strong>spread.<br />
On the basis of all six systematic reviews we conclu<strong>de</strong>d in Table 2.2 (page 19) that there<br />
were conflicting results in relation to the <strong>volume</strong>-outcome association betwe<strong>en</strong> <strong>volume</strong><br />
(hospital or interv<strong>en</strong>tionist) and mortality in case of pati<strong>en</strong>ts un<strong>de</strong>rgoing a PCI for mixed<br />
indications (elective and primary) and betwe<strong>en</strong> hospital <strong>volume</strong> and emerg<strong>en</strong>cy CABG<br />
rate. The term conflicting results means that there are primary studies that indicate a<br />
positive relation with <strong>volume</strong> and other studies that indicate a negative relation with<br />
<strong>volume</strong>. On the other hand, we conclu<strong>de</strong>d that there was an inverse relation betwe<strong>en</strong><br />
<strong>volume</strong> (hospital or interv<strong>en</strong>tionist) and mortality for primary PCI, and betwe<strong>en</strong><br />
interv<strong>en</strong>tionist <strong>volume</strong> and emerg<strong>en</strong>cy CABG rate.